19:32 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

vTv to propose path forward for AD candidate despite Phase III miss

vTv Therapeutics Inc. (NASDAQ:VTVT) said azeliragon (TTP488) missed the co-primary endpoints compared with placebo in Part B of the Phase III STEADFAST trials to treat mild Alzheimer’s disease. Despite the miss, the company said it...
13:36 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s disease candidate missed the co-primary endpoints in Part A of the Phase III STEADFAST trials to treat mild AD. STEADFAST...
23:11 , Apr 9, 2018 |  BC Extra  |  Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s disease candidate missed the co-primary endpoints in Part A of the Phase III STEADFAST trials to treat mild AD....
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
03:13 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

vTv completes enrollment in Phase III of RAGE antagonist for AD

vTv Therapeutics LLC (NASDAQ:VTVT) completed enrollment of about 800 patients with mild Alzheimer’s disease in the Phase III STEADFAST trial of azeliragon (TTP488). The double-blind, placebo-controlled, North American trial is evaluating the change from baseline...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor for advanced glycation endproducts (RAGE)

Neurology INDICATION: Stroke Mouse studies suggest inhibiting RAGE could help treat stroke that occurs in patients with hyperglycemia. In a hyperglycemic mouse model of ischemic stroke, RAGE knockout decreased infarct volume compared with normal RAGE expression. Next...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

Azeliragon: Additional Phase IIb data

Additional data from an 18-month, double-blind, U.S. Phase IIb trial in 399 patients with mild to moderate AD showed that once-daily 5 mg oral azeliragon significantly delayed time to cognitive deterioration in patients with mild...
03:44 , Jul 31, 2015 |  BC Extra  |  Financial News

vTv falls after $117.2M IPO

vTv Therapeutics Inc. (NASDAQ:VTVT) lost $4.17 (28%) to $10.83 in its first day of trading Thursday after raising $117.2 million through the sale of 7.8 million shares at $15 in an IPO underwritten by Piper...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Azeliragon: Phase III started

vTv (formerly TransTech Pharma LLC) began the double-blind, placebo-controlled, North American Phase III trial to evaluate 5 mg oral azeliragon once daily for 18 months in about 800 patients receiving acetylcholinesterase inhibitors and/or memantine....
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

TTP488: SPA received

TransTech said it received an SPA from FDA for a double-blind, placebo-controlled Phase III trial to evaluate 5 mg oral TTP488 once daily for 18 months in about 800 patients with mild AD receiving standard...